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Mice lacking the transcription factor T-bet in the
innate immune system develop microbiota-depen-
dent colitis. Here, we show that interleukin-17A
(IL-17A)-producing IL-7Ra+ innate lymphoid cells
(ILCs) were potent promoters of disease in
Tbx21/Rag2/ ulcerative colitis (TRUC) mice.
TNF-a produced by CD103CD11b+ dendritic cells
synergized with IL-23 to drive IL-17A production by
ILCs, demonstrating a previously unrecognized layer
of cellular crosstalk between dendritic cells and ILCs.
We have identified Helicobacter typhlonius as a key
disease trigger driving excess TNF-a production
and promoting colitis in TRUC mice. Crucially,
T-bet also suppressed the expression of IL-7R,
a key molecule involved in controlling intestinal ILC
homeostasis. The importance of IL-7R signaling in
TRUC disease was highlighted by the dramatic
reduction in intestinal ILCs and attenuated colitis
following IL-7R blockade. Taken together, these
data demonstrate the mechanism by which T-bet
regulates the complex interplay between mucosal
dendritic cells, ILCs, and the intestinal microbiota.
INTRODUCTION
Interactions between the innate immune system and the intes-
tinal microbiota play an important role in the maintenance of
mucosal homeostasis. Genetic variation in innate immune
components, such as pattern recognition receptors, is associ-
ated with Crohn’s disease (Barrett et al., 2008) and alters the
susceptibility of mice to experimental inflammatory bowel
disease (IBD) (Araki et al., 2005; Rakoff-Nahoum et al., 2004;674 Immunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc.Vijay-Kumar et al., 2007). Innate immune pathways can also
drive gut inflammation, and numerous models of IBD are well
characterized in mice lacking adaptive immunity (Buonocore
et al., 2010; Kim et al., 2006; Li et al., 1998; Uhlig et al., 2006).
Accordingly, there is considerable interest in understanding the
mechanisms controlling innate immune activation in the gut.
T-bet, a T-box-family transcription factor, has emerged as
a critical regulator of intestinal homeostasis and innate immunity,
andmice lacking T-bet in the innate immune compartment spon-
taneously develop IBD (Garrett et al., 2007). The intestinal micro-
biota play a crucial role in TRUC (Tbx21/Rag2/ ulcerative
colitis) disease. IBD in this model resolves following treatment
with antibiotics (Garrett et al., 2010; Garrett et al., 2007) and pro-
biotics (Veiga et al., 2010) and does not occur when mice are
raised in a germ-free environment (Garrett et al., 2010). Low-
grade intestinal inflammation is also communicable to T-bet-
sufficient mice, consistent with the notion that a colitogenic
community of intestinal microbes triggers disease. Bacteria
such as Klebsiella pneumoniae and Proteus mirabilis cultured
from the feces of TRUC mice correlate with colitis but may not
becausative (Garrett et al., 2010), given that colitis per sedisrupts
intestinalmicrobial ecology, resulting in nonspecific expansion of
Enterobacteriaceae (Lupp et al., 2007; Stecher et al., 2007).
Importantly, the innate immune mechanisms responsible for
maintaining chronic TRUC disease are not resolved. Early stages
of disease are characterized by dysregulated TNF-a expression
by colonic dendritic cells (DCs), and disease can be ameliorated
by neutralizing TNF-a antibodies. However, beyond 12 weeks of
age, TNF-a antibodies are ineffective (Garrett et al., 2009). The
innate immune inflammatory pathways responsible for chronic
colitis inTRUCmiceareof interest because later stagesofdisease
recapitulate some aspects of human ulcerative colitis (UC), with
the proximal extension of inflammation, the development of fulmi-
nant colitis, andneoplasia (Garrett et al., 2007;Garrett et al., 2009).
Recently, the repertoire of cells that produce key cytokines
implicated in IBD pathogenesis, such as interferon-g (IFN-g)
and interleukin-17A (IL-17A), has been extended to include
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T-bet Regulates Innate Immunitya population of cells termed innate lymphoid cells (ILCs) (Buono-
core et al., 2010; Takatori et al., 2009). We hypothesized that
ILCs would be responsible for driving fulminant TRUC disease
and that T-bet would play a central role in regulating the patho-
genicity of these cells.
RESULTS
Chronic TRUC Disease Is ILC Dependent
First, we tested the hypothesis that ILCs contribute to the patho-
genesis of IBD in TRUC mice. We investigated the immune
response in TRUCmice aged >12 weeks, an age at which TNF-a
blockade loses efficacy and severe colitis emerges. We specifi-
cally looked for expression of IFN-g, IL-17A, and IL-22 cytokines
produced by innate immune cells, including ILCs. Activation of
unfractionated colonic lamina propria leukocytes (cLPLs) from
TRUC mice induced many IL-17A-expressing CD45+ immune
cells. However, few IFN-g- or IL-4-expressing cells were seen
(Figure 1A). In TRUCmice, themajority of IL-17A-expressing cells
were CD90hi, CCR6+, RORgt+, Sca-1+, and IL-7Ra+ (Figure 1B),
consistent with the phenotype of ILCs (Buonocore et al., 2010;
Sonnenberg et al., 2011). Intestinal IL-17A+CD90+ cells were
CD4, NKp46, CD11c, and Gr-1. Notably, the cytokine re-
sponse of CD90+ ILCs from TRUC mice was dominated by the
expression of IL-17A and, to a lesser extent, IL-22; however, IFN-
g-expressing cells were conspicuously infrequent (Figure 1C).
For testing the functional significance of ILCs in chronic TRUC
IBD, a depleting CD90 monoclonal antibody (mAb) was adminis-
tered to TRUC mice. In contrast to effects on isotype-control-
treated mice, anti-CD90 substantially reduced the number of
CD90+ cells and the number of IL-17A-producing cells in
TRUC mice (Figure 1D; Figure S1A available online) and amelio-
rated disease, including significantly improving colitis scores
(Figure 1E), reduced colon mass, and reduced spleenmass (Fig-
ure S1B). In contrast, mice treated with control antibody devel-
oped fulminant colitis and severe histological changes charac-
teristic of chronic TRUC IBD, including epithelial hyperplasia,
goblet cell depletion, crypt destruction, crypt abscess formation,
and infiltration of the lamina propria with mononuclear cells and
neutrophils (Figure 1E).
To further investigate the role of ILCs in TRUC IBD, we gener-
ated Tbx21/Rag2/Il2rg/ triply deficient mice that addition-
ally lack the common g chain cytokine receptor. Il2rg/ mice
have >90% reduction in the number of ILCs in secondary
lymphoid organs, such as the spleen (Kim et al., 2005). We
reasoned that intestinal ILC homeostasis would also be depen-
dent on this receptor and therefore might provide additional
insights into the requirements for ILCs in TRUC disease.
Crucially, Tbx21/Rag2/Il2rg/ mice had severely dimin-
ished numbers of intestinal ILCs, failed to develop colitis, and
had undetectable levels of Il17a messenger RNA (mRNA) in the
colon (Figures 1F, 1G, and S1C–S1E). Taken together, these
data demonstrate that chronic TRUC IBD is dependent on
ILCs and that the common g chain cytokine receptor plays an
important role in intestinal ILC homeostasis.
Chronic TRUC IBD Is Dependent on the IL-23:IL-17 Axis
In view of the dominant IL-17 response observed in chronic
TRUC IBD, we investigated the role of the IL-23:IL-17 axis inthis disease. We hypothesized that IL-17A blockade alone would
be sufficient to ameliorate disease. In contrast to control anti-
body treatment, administration of a neutralizing IL-17A antibody
markedly improved colitis (Figures 2A and S2A). Indeed, 71%
(5/7) of anti-IL-17A-treated mice had complete resolution of
colitis (colitis score = 0). Consistent with the biological activities
of IL-17A, antibody blockade also prevented the accumulation of
F4/80CD11b+Gr-1hi granulocytes infiltrating the colon (Fig-
ure 2B). However, the proportions of cLP F4/80+ macrophages
were comparable in treated and untreated mice.
It has recently been reported that IL-23 also activates innate
immunity, including driving innate IL-17 production (Takatori
et al., 2009). Therefore, we investigated the role of IL-23 in
TRUC IBD. IL-17A protein was inducible by IL-23 and was
most pronounced in the colon and draining lymph nodes
compared to the spleen of TRUCmice (Figure 2C). IL-23 induced
the expression of IL-17A and, to a lesser extent, IL-22 by ILCs
from TRUC mice but had little effect on IFN-g production (Fig-
ure 2D). IL-23-induced ILC activation was also relevant in vivo.
Administration of an IL-23p19 mAb significantly reduced
IL-17A expression in ex vivo explant cultures (Figure 2E).
Crucially, IL-23p19 neutralization also markedly improved colitis
(Figure 2F). These data identify a central role for the IL-23:IL-17
axis in chronic intestinal inflammation in TRUC mice.
Helicobacter typhlonius Is a Key Component of the
Intestinal Microbiota Driving IBD in TRUC Mice
The composition of the intestinal microbiota is now recognized
to profoundly impact intestinal immunity. Therefore, in order to
better understand the immune pathways activated by the colito-
genic microbiota colonizing TRUC mice, we sought to define
which components of themicrobiota were responsible for driving
disease. Prior attempts to define causative bacteria have been
hampered by a lack of appropriate control animals. However,
we rederived a novel colony of Tbx21/Rag2/ mice that,
unlike their isogenic TRUC counterparts, did not develop spon-
taneous colitis (Figures 3A and 3B). We termed these animals
TRnUC (Tbx21/Rag2/ non-UC) mice. To identify potentially
causative bacterial species, we compared the intestinal bacterial
communities of TRUC and TRnUCmice by sequencing bacterial
16S ribosomal RNA (rRNA) genes. Individual samples shared
broad similarities in community structure with other members
of the same colony but were distinct from mice in the other
colony (Figure 3C). As expected, all samples were dominated
at the phylum level by Firmicutes,Bacteroidetes, Proteobacteria,
Actinobacteria, and Deferribacteres (Figure S3A). At the phylum
level, notable differences included an increased abundance of
sequences from the Proteobacteria phylum and an increased
ratio of Firmicutes to Bacteroidetes in TRUC mice (Figure S3B).
However, just 12 species-level operational taxonomic units
(OTUs) were consistently present in all TRUC mice and always
absent from TRnUC mice. One of these sequences matched
with 100% identity to the proteobacterial species Helicobacter
typhlonius (Table S1). Specific PCR and DNA sequencing of
the amplicon confirmed that H. typhlonius colonization was
confined to TRUCmice (Figures 3D and S3C). Crucially, inocula-
tion of TRnUC mice with pure cultures of H. typhlonius by oral
gavage triggered severe colitis that was histologically indistin-
guishable from TRUC IBD (Figure 3E). H. typhlonius and colitisImmunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc. 675
Figure 1. Chronic TRUC IBD Is Dependent on CD90+RORgt+CCR6+IL-7R+ ILCs
(A) Intracellular cytokine expression by live, CD45+ cLP cells from TRUC mice following stimulation with PMA and ionomycin.
(B) Phenotype of live, CD45+CD90hiIL-17A+ cells (red) in comparison with CD90IL-17A cells (black) from the mLN and cLP of TRUC mice following stimulation
with PMA and ionomycin.
(C) Intracellular cytokine expression by lineage (CD11c, NKp46, Gr-1) CD90hi ILCs frommLN of TRUCmice. Cells were stimulated with PMA and ionomycin.
(D) IL-17A and CD90 expression in live, CD45+ cLP cells following in vivo administration of anti-CD90 or control antibody to TRUC mice (left panel). Cells were
stimulated with PMA and ionomycin. Right panel shows absolute numbers of IL-17A-producing cells in the cLP of these TRUC mice following CD90 depletion
(n = 4) or control mAb treatment (n = 5). Results show mean, and error bars represent SEM. Also see Figure S1A.
(E) Colonmicrographs and colitis scores following depleting anti-CD90 treatment in TRUCmice. Results showmean, and error bars represent SEM. Other clinical
features are shown in Figure S1B.
(F) Flow cytometry histogram showing the % CD90hi cells in the cLP of TRUC and TRUC 3 Il2rg/ mice. Also see Figure S1C.
(G) Colitis scores of TRUC (n = 14) and TRUC 3 Il2rg/ (n = 5) mice. Results show mean, and error bars represent SEM. Other clinical features are shown in
Figure S1D.
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T-bet Regulates Innate Immunitycould also be transmitted to TRnUC mice cohoused with TRUC
mice (data not shown). These data are consistent with an impor-
tant role for H. typhlonius in triggering disease in TRUC mice.
T-bet Is Required for Optimal Expression of IFN-g by
Intestinal ILCs, and in Its Absence ILCs Selectively
Express IL-17A
The highly polarized IL-17A response and lack of significant
IFN-g expression observed in ILCs from TRUC mice led us to676 Immunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc.speculate that T-bet would be required for optimal production
of IFN-g by ILCs. To test this hypothesis, we compared the
phenotypes of Tbx21+/+ and Tbx21/ intestinal ILCs in
H. typhlonius-associated colitis in TRnUC and Rag2/ mice.
Ex vivo explant cultures from TRnUC mice gavaged with
H. typhlonius produced less IFN-g and more IL-17A in compar-
ison to Rag2/ mice (Figure 4A). Intracellular cytokine staining
showed that ILCs from Rag2/ mice predominantly produced
IFN-g, whereas ILCs from TRnUC mice mostly produced
Figure 2. Chronic TRUC IBD Is Dependent
on the IL-23:IL-17 Axis
(A) Colon micrographs of TRUC mice following
treatment with anti-IL17A (n = 7) or control anti-
body (n = 8). Also see Figure S2A for histology
scores.
(B) The proportion (%) of CD45+Gr-1hiCD11b+F4/
80 granulocytes and F4/80+CD11b+ macro-
phages in the cLP of TRUC mice treated with anti-
IL17A or isotype. A representative flow cytometry
histogram is also shown (right panel).
(C) IL-17A concentration in the supernatants of
cultured cLPLs, mLN cells, and splenocytes from
TRUC mice, in the presence (+IL-23) or absence
(medium alone) of recombinant IL-23, measured
by ELISA. Results show mean, and error bars
represent SEM.
(D) Intracellular cytokine expression in linCD90hi
ILCs frommLNof TRUCmice following stimulation
with IL-23.
(E) IL-17A concentration in culture supernatants of
explant organ culture of TRUC mice treated with
anti-IL-23p19 or control antibody, measured by
ELISA. Results show mean, and error bars repre-
sent SEM.
(F) Colitis scores, colon mass, and spleen mass of
TRUC mice treated with anti-IL-23p19 or control
antibody. Results show mean, and error bars
represent SEM.
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T-bet Regulates Innate ImmunityIL-17A (Figure 4B). Similar results were also seen in another
model of ILC-mediated intestinal inflammation induced by
agonistic CD40 mAbs (Buonocore et al., 2010). Anti-CD40
induced wasting disease, splenomegaly, increased colonic
mass, and infiltration of the colon with Gr-1hi granulocytes
(Figures 4C and S4A). Following disease induction, ILCs from
Rag2/ mice expressed T-bet, which positively correlated
with IFN-g expression and inversely correlated with IL-17A
expression. Conversely, IFN-g expression was markedly dimin-
ished in ILCs from TRnUCmice, and instead these cells predom-
inantly produced IL-17A (Figure 4D). Consistent with impaired
IFN-g production, wasting disease was delayed in T-bet-defi-
cient mice; however, intestinal disease, as measured by
increased colonic mass, occurred with comparable severity in
this model (Figure S4B). These data indicate that T-bet is
required for optimal expression of IFN-g by intestinal ILC and
that in the absence of T-bet these cells produce excess IL-17A.
CD103–CD11b+ Colonic DCs Are Major Producers of
TNF-a, which Potentiates IL-23-Induced Innate IL-17
Expression
Deregulated TNF-a production by colonic CD11c+ DCs is a hall-
mark feature of TRUC IBD (Garrett et al., 2007; Garrett et al.,
2009). Therefore, we investigated whether H. typhlonius was
capable of inducing TNF-a expression by colonic DCs in TRnUCImmunity 37, 674–684,mice and also how this might impact
innate IL-17 production. Oral inoculation
with H. typhlonius resulted in increased
abundance of Tnfa transcripts in the
colon of TRnUC mice to levels similar to
those observed in TRUCmice (Figure 5A).CD11chi major histocompatibility complex class II+ intestinal
DCs can be divided into subsets based on surface expression
of CD103 and CD11b (Varol et al., 2009). The frequency of
each colonic DC subset was comparable in Rag2/ and TRnUC
mice (Figure 5B). CD103CD11b+ DCs were the principal subset
responsible for TNF-a production and were also the most
frequent colonic DC subset. Notably, in the absence of T-bet,
TNF-a expression by CD103CD11b+ DCs was enhanced 2 to
3 fold (Figure 5C). We sought to determine how enhanced
TNF-a production by CD103CD11b+ intestinal DCs might
impact ILC activation in TRUC IBD. Although on its own, re-
combinant TNF-awas unable to induce innate IL-17A production
by unfractionated mesenteric lymph node (mLN) cells from
TRUC mice, it markedly potentiated IL-23-induced IL-17A
production (Figure 5D). We also investigated the functional
significance of TNF-a-potentiated innate IL-17 expression
in vivo. As well as ameliorating H. typhlonius-induced colitis in
TRnUC mice (Figure 5E), TNF-a blockade also substantially
reduced colonic Il17a transcripts, consistent with the possibility
that TNF-a-augmented IL-17A production is physiologically rele-
vant in ILC-mediated colitis (Figure 5F).
TRUC IBD Is Critically Dependent on IL-7 Signaling
We next determined whether T-bet might regulate other genes
involved in ILC biology. The majority of ILCs in TRUC diseaseOctober 19, 2012 ª2012 Elsevier Inc. 677
Figure 3. H. typhlonius Is a Key Component of the Intestinal Microbiota Driving IBD in TRUC Mice
(A) Photomicrographs of the distal colon of 12-week-old TRUCmice with agematched, Tbx21/Rag2/mice that did not develop spontaneous colitis (TRnUC)
(left panel). Macroscopic appearances of the colon of 16-week-old TRUC and TRnUC mice (right panel).
(B) Colon and spleen mass in 12- to 16-week-old TRUC, TRnUC, and Rag2/ mice. *p < 0.0001 (TRUC versus TRnUC or Rag2/).
(C) Cluster dendrogram showing overall intestinal bacterial community membership clustering in TRUC and TRnUC mice. Families colored brown or yellow
belong to the Bacteroidetes phylum; those in blue or purple belong to the Firmicutes phylum. SFB, segmented filamentous bacteria. Also see Figure S3B.
(D) Agarose gel electrophoresis (2%) of PCR products following H. typhlonius-specific PCR performed on bacterial DNA isolated from fresh fecal samples from
TRUC and TRnUC mice. The H. typhlonius-specific PCR product is 122 bp.
(E) Colitis scores in TRnUC and Rag2/ mice following inoculation with pure cultures of H. typhlonius by oral gavage. Results show mean, and error bars
represent SEM.
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T-bet Regulates Innate Immunityand other ILC-associated diseases (Buonocore et al., 2010; Son-
nenberg et al., 2011) express IL-7 receptor (IL-7R), which
appears to play an important role in the homeostasis of several
immune cell populations (Crellin et al., 2010; Satoh-Takayama
et al., 2010; Schmutz et al., 2009). Indeed, intestinal ILCs are re-
ported to be absent or reduced in Il7/mice (Vonarbourg et al.,
2010). IL-7R is also a member of the common g chain cytokine
receptor family, which plays an indispensible role in intestinal
ILC homeostasis, as we have already demonstrated (Figures
1F and 1G). Although ILCs are too infrequent to perform chro-
matin immunoprecipitation sequencing, we were able show
that T-bet binds at the Il7ra locus in CD4+ T cells. T-bet binding
was enriched at the transcriptional start site of the Il7ra gene in678 Immunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc.a region highly conserved in mammals (Figure 6A). Next, we
asked whether T-bet was a transcriptional activator or repressor
of the Il7ra gene. Retroviral transduction of T-bet into CD4+
T cells from Tbx21/Ifng/mice resulted in amarked reduction
in Il7ra mRNA expression (Figure 6B). Crucially, Il7ra transcripts
were reduced in T-bet-expressing ILCs from Rag2/ mice in
comparison with T-bet-deficient ILCs from TRnUC mice (Fig-
ure 6C), consistent with the possibility that T-bet represses IL-
7Ra expression in ILCs in a physiologically relevant disease
setting. IL-7R signaling was also functionally important in intes-
tinal ILC homeostasis and TRUC disease. IL-7R blockade signif-
icantly reduced ILC numbers in TRUC mice, although ILCs in
secondary lymphoid tissue appeared to be more sensitive to
Figure 4. T-bet Is Required for Optimal
Expression of IFN-g by Intestinal ILCs, and
in the Absence of T-bet ILCs Selectively
Produced IL-17A
(A) Cytokine concentrations in ex vivo explant
cultures from Rag2/ (n = 5) and TRnUC (n = 5)
mice following gavage with H. typhlonius,
measured by ELISA. Results show mean, and
error bars represent SEM.
(B) Intracellular cytokine expression in live
CD45+CD90hi cLP ILCs from Rag2/ and TRnUC
mice inH. typhlonius-associated colitis. Cells were
stimulated with PMA and ionomycin.
(C) Organ mass in Rag2/ mice following treat-
ment with agonistic CD40 mAbs or control anti-
body. Also see Figure S4A for other clinical
features.
(D) Flow cytometry histogram demonstrating the
proportion of Gr-1hi granulocytes in the cLP of
Rag2/ mice following anti-CD40 or control mAb
administration.
(E) Representative flow cytometry plot showing
intracellular cytokine and T-bet expression in
linCD90+ ILCs from mLN of Rag2/ and TRnUC
mice following CD40 mAb treatment.
(F) Proportions of IL-17A+ or IFN-g+CD90+ ILCs in
the cLP of Rag2/ or TRnUC mice following
administration of anti-CD40.
Immunity
T-bet Regulates Innate Immunityblockade than intestinal ILCs, given that CD90hiIL-7Ra+ ILCs
were almost completely eliminated from the spleen, whereas
ILC numbers in the colon were diminished 3 to 4 fold following
anti-IL-7R treatment (Figure 6D). IL-7R blockade also improved
disease parameters (Figure 6E), demonstrating that IL-7R
signaling plays an important role in intestinal ILC homeostasis
and controls ILC-mediated mucosal pathology.
DISCUSSION
Our results shed new light on the TRUC model of IBD and
provide novel insight into the regulation of ILC-mediated
mucosal pathology. We have demonstrated that ILCs potently
promoted colitis in TRUC mice. Excess TNF-a produced by
CD103CD11b+ colonic DCs synergized with IL-23 to induce
IL-17A expression by ILCs, demonstrating a previously unrecog-
nized layer of crosstalk between DCs and ILCs. We have also
identified a constituent of the TRUC intestinal microbiota that
augmented colonic TNF-a production and triggered severe
colitis in rederived, otherwise healthy, isogenic Tbx21/
Rag2/ hosts. Lastly, we have shown that T-bet repressedImmunity 37, 674–684,the expression of IL-7R, signaling through
which is critical for intestinal ILC homeo-
stasis and TRUC IBD. Together, these
data demonstrate that T-bet controls
a transcriptional program in the intestinal
innate immune system that profoundly
impacts the balance between the mainte-
nance or loss of intestinal homeostasis.
These data also highlight an important
aspect of transcription factor biology,wherein a single transcription factor simultaneously regulates
multiple target genes involved in a particular immune pathway.
In a similar way, we have previously shown that T-bet binds at
the promoter of >800 protein-encoding genes in T helper 1
(Th1) cells, which results in the activation of numerous key genes
involved in the Th1 cell response (Jenner et al., 2009), ensuring
that an efficient, coordinated and appropriately polarized
response ensues (Powell et al., 2010).
These new insights necessitate an update in our under-
standing of the TRUC model of IBD. We have shown that the
key cellular mediators of chronic intestinal inflammation in
TRUC mice were CD90hiRORgt+CCR6+IL-7Ra+ ILCs. ILCs
were the primary source of IL-17A in this disease, and ILC deple-
tion reversed colitis. Strikingly, in the absence of T-bet, intestinal
ILCs producedminimal amounts of IFN-g and instead selectively
expressed IL-17A. These data suggest that pronounced IL-17
production by ILCs, even when unaccompanied by substantial
IFN-g coexpression, is sufficient to induce severe intestinal
pathology. These data also indicate that T-bet is necessary for
optimal IFN-g expression by intestinal ILCs. Diminished
innate production of IFN-g observed in T-bet-deficient hostsOctober 19, 2012 ª2012 Elsevier Inc. 679
Figure 5. CD103–CD11b+ Colonic DCs Are Major Producers of TNF-a, which Potentiates IL-23-Induced Innate IL-17 Expression
(A) Real-time PCR measuring Tnfa transcripts in the colons of Rag2/, TRnUC, TRnUC mice infected with H. typhlonius (+ HT), and TRUC mice. Results show
mean, and error bars represent SEM.
(B) DC subset frequency in the colon of TRnUC and Rag2/ mice following inoculation with H. typhlonius. Results show mean, and error bars represent SEM.
(C) Spontaneous intracellular TNF-a production by different intestinal DC populations from Rag2/ and TRnUC mice following inoculation with H. typhlonius,
showing representative flow cytometry plots (left panel) and statistical analysis (n = 5 per group) (right panel).
(D) IL-17A production by unfractionated mLN cells from TRUCmice following incubation with the stimuli described. (-) indicates unstimulated cells. Results show
mean, and error bars represent SEM.
(E) Colitis scores in TRnUCmice inoculated with H. typhlonius following treatment with a blocking TNF-amAb or control antibody. Results showmean, and error
bars represent SEM.
(F) Real-time PCR quantifying Il17a transcripts following treatment with a neutralizing TNF-a mAb or control isotype.
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T-bet Regulates Innate Immunityprobably accounts for the delayed wasting disease observed in
anti-CD40-induced disease, consistent with previous reports
showing that systemic disease in this model is mediated by the680 Immunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc.IL-12/IFN-g pathway (Uhlig et al., 2006). These data also imply
that T-bet impacts innate immunity in a tissue-specific manner
and that intestinal rather than systemic disease is favored in its
Figure 6. TRUC Disease Is Critically Depen-
dent on IL-7R Signaling
(A) UCSC Genome Browser image is shown for
T-bet binding at the il7ra locus in Tbx21+/+ versus
Tbx21/CD4+ Th1 cells following stimulation with
PMA and ionomycin for 4 hr. Chromatin was
immunoprecipitated, crosslinked, and prepared as
described previously (Jenner et al., 2009).
Samples were sequenced with an Illumina
Genome Analyzer II-x. The vertical axis depicts the
number of tags per million total sequences, with
the genomic location running along the horizontal
axis. The direction of transcription is indicated by
arrows. Red arrows depict three sites of T-bet
binding at the Il7ra locus
(B) Relative abundance of Il7ramRNA in Tbx21/
Ifng/ CD4+ T cells following retroviral trans-
duction with empty vector (RV) or T-bet (T-bet RV).
Cells were activated with PMA and ionomycin.
(C) Relative abundance of Il7ra mRNA in fluores-
cence-activatedcell-sortedTbx21/ andTbx21+/+
CD90hi ILCs isolated from mLN of TRnUC and
Rag2/ mice following induction of disease with
anti-CD40. Results show mean, and error bars
represent SEM.
(D) Representative flow cytometry plot of splenic
CD90+IL-7R+ ILCs (left panel) and absolute
numbers (right panel) of ILCs in the spleen and
colon of TRUCmice, following treatment with anti-
IL7R or control antibody.
(E) Colitis score (left panel), spleen mass (middle
panel), and colon mass (right panel) in TRUC mice
following treatment with anti-IL-7R or control
antibody. Results show mean, and error bars
represent SEM.
Immunity
T-bet Regulates Innate Immunityabsence. In contrast to other studies showing that ILC-mediated
intestinal pathology requires dual blockade of IL-17 and IFN-g to
abrogate disease (Buonocore et al., 2010), in TRUC IBD IL-17A
blockade alone reversed disease. It is possible that IL-17A
blockade alone would not fully prevent ILC-mediated pathology
in T-bet-sufficient hosts because, unlike TRUC mice, these
animals can still mount effective IFN-g responses. These obser-
vations offer potentially relevant insights into clinical trials evalu-
ating cytokine blockade in human IBD. Antibody blockade of
IFN-g is largely disappointing in Crohn’s disease (Reinisch
et al., 2010), and preliminary data appear to show that anti-IL-
17A therapy lacks efficacy or even exacerbates Crohn’s disease
(W. Hueber et al., 2011, J. Crohns Colitis, abstract). Although
redundancy and plasticity of cytokine responses potentially
account for the lack of efficacy observed following anti-IL-17
or anti-IFN-g monotherapy, it is now appreciated that IBD is
heterogeneous in terms of clinical phenotype, mucosal immune
response, and genetic risk. In the future it is conceivable that IBD
patients will be stratified according to their genetic profile or
mucosal immune response phenotype in order to better guide
selective cytokine blockade in individual patients. However,
blockade of IL-12p40, which is required for biological activity
of both IL-12 and IL-23 and hence is a common upstream signal
for both IL-17A and IFN-g production, shows therapeutic
promise in IBD (Mannon et al., 2004).
We also identified H. typhlonius as a key colitogenic compo-
nent of the TRUC intestinal microbiota. This bacterium wasever present in the intestinal microbiota of diseased TRUC
mice and was consistently absent from rederived, disease-free
Tbx21/Rag2/ mice. Oral inoculation with pure cultures of
H. typhlonius was also sufficient to trigger disease.
H. typhlonius induced markedly more severe IBD in T-bet-defi-
cient hosts, confirming that T-bet deficiency confers heightened
susceptibility to IBD following exposure to particular intestinal
microbes. H. typhlonius is a Gram-negative, microaerophilic,
urease-negative, spiral-rod-shaped bacterium that is closely
related to Helicobacter hepaticus (Franklin et al., 2001).
H. typhlonius was first identified in the colon of Il10/ mice
that also develop microbiota-dependent IBD (Fox et al., 1999;
Franklin et al., 2001). Evidence is mounting in humans to suggest
that IBDmay also be linked to expansion of colitogenic microbes
and/or contraction of protective bacteria. Adherent-invasive
Escherichia coli are associated with IBD and have been impli-
cated in disease pathogenesis (Chassaing et al., 2011).
Conversely, intestinal colonization with Faecalibacterium praus-
nitzii, a bacterium with anti-inflammatory properties (Sokol et al.,
2008), is negatively correlated with Crohn’s disease (Joossens
et al., 2011) and UC (Sokol et al., 2009). The TRUC model of
IBD therefore highlights how the genetic composition of the
host shapes interactions with the intestinal microbiota and
impacts colitis susceptibility.
We have also shown that colonic TNF-a, which was primarily
produced by CD103CD11b+ DCs, was augmented in the
absence of T-bet. Although by itself TNF-a did not appear toImmunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc. 681
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IL-23 it proved to be a potent stimulus for IL-17 production.
These data indicate that crosstalk between DCs and ILCs may
be important in the regulation of intestinal homeostasis and
that T-bet plays a crucial role in regulating this interaction. In
the absence of T-bet, CD103CD11b+ DCs overproduced
TNF-a, which synergized with IL-23 to induce IL-17A production
by IL-7R+ ILCs. Therefore, in the appropriate microbiological
context, T-bet deficiency favors excess intestinal production of
TNF-a and IL-17A, which appears to be a potently colitogenic
cytokine milieu.
We have also shown that IL-7R blockade attenuated ILC-
mediated IBD. Similar to the situation in Il2rg/ mice, which
are unable to signal through IL-7R, specific IL-7R blockade
significantly diminished colonic ILCs and suppressed colitis.
Interestingly, unlike splenic ILCs that were almost completely
eliminated, colonic ILCs were less prone to depletion by IL-7R
blockade, indicating that additional IL-7-independent ILC
survival signals may exist in the colon or in inflamed tissue.
The importance of IL-7R signaling in IBD is also implied by recent
data identifying SNPs at the IL7R locus in patients with UC (An-
derson et al., 2011). We have shown that T-bet bound at the Il7ra
promoter and, when overexpressed, reduced Il7ra mRNA
expression 20 fold in T cells in an IFN-g-independent manner,
consistent with the possibility that T-bet is a transcriptional
repressor of the Il7ra locus. In keeping with this, Il7ra mRNA
was increased in ILCs from T-bet-deficient hosts.
In conclusion, these results demonstrate that T-bet is a crucial
gatekeeper of innate inflammatory pathways at the intestinal
barrier surfaces, where it regulates the balance between
mucosal homeostasis and inflammation. In the absence of
T-bet, particular microbes trigger overproduction of colonic
TNF-a, which drives chronic colitis that is mediated by innate
lymphoid cells preferentially producing IL-17A.EXPERIMENTAL PROCEDURES
Animal Husbandry
Balb/C Tbx21/ (Jackson Labs), Rag2/ (Jackson Labs), Rag2/Il2rg/
(Taconic), and Ifng/ (Jackson Labs) mice were sourced commercially. A
colony of colitis-free TRnUC mice was generated and remotely maintained
at geographically distinct isolators from the TRUC colony that was descendant
from the originally described TRUCmice (Garrett et al., 2007). All animal exper-
iments were conducted in accredited facilities in accordance with the UK
Animals (Scientific Procedures) Act 1986 (Home Office license number PPL
70/6792).
Isolation of cLPLs
Colons were cut longitudinally, fecal material was removed, and colons
were washed with PBS. Colons were then cut in to 5 mm segments, and
the epithelium was removed through incubation with Hank’s balanced
salt solution (HBSS) without Mg2+ or Ca2+ (Invitrogen), supplemented with
10% fetal calf serum (FCS Gold, PAA Laboratories), 10 mM HEPES (Fisher
Scientific), 100 IU/ml penicillin, and 100 mg/ml streptomycin (Invitrogen)
and EDTA (5 mM). Tissue was then mechanically disrupted using Gentle-
MACS (Miltenyi Biotec), followed by collagenase digestion through incuba-
tion of the crude cell mixture in RPMI-1640 medium (PAA Laboratories)
supplemented with 25 mg/ml collagenase D (Roche), 10 mg/ml DNase I
(Roche), and 1.5mg/ml dispase (Roche) for 45 min in a shaking water bath
(37C). Cells were resuspended in 40% Percoll (GE Healthcare) and layered
on 80% Percoll prior to centrifugation, and the cLPL-enriched population
was harvested.682 Immunity 37, 674–684, October 19, 2012 ª2012 Elsevier Inc.Histology
One centimeter segments of colon were fixed in 10% paraformaldehyde and
embedded in paraffin blocks. Five micrometer sections were stained with
hematoxylin and eosin. For immunofluorescence, colon tissue was removed
and snap frozen in Jung tissue-freezing medium (Leica Microsystems). Seven
micrometer cryostat sections were fixed in acetone, blocked (20% normal
horse serum, PAA Laboratories), and incubated with fluorescein-isothiocya-
nate-conjugated anti-CD90.2 (eBioscience). Nuclei were counterstained with
1 mg/ml DAPI (Invitrogen). Colitis scores comprising epithelial hyperplasia
(0–3), epithelial injury (0–3), polymorphonuclear infiltrate (0–3), and mononu-
clear infiltrate (0–3) were reported in a blinded fashion (T.T.M.) as described
previously (Garrett et al., 2007).
Flow Cytometry
Intracellular cytokine expression was measured after cells were stimulated
with IL-23 (20 ng/ml) or with PMA (50 ng/ml,) and ionomycin (1 mg/ml, both
Sigma-Aldrich) for 4 hr, with monensin (2 mM) added for the final 2 hr at
37C. In order to measure spontaneous cytokine production by DCs, cells
were incubated for 4 hr at 37C in the presence of monensin without additional
stimuli. Surface-staining antibodies were added together with LIVE/DEAD
stain (Invitrogen) for 20 min at room temperature. Cells were fixed in 1% para-
formaldehyde and permeabilized (eBioscience permeabilization buffer), and
intracellular staining was performed for 30 min at 4C. Antibodies were from
eBioscience unless otherwise stated: a-CD45 (30-F11), a-CD4 (RM4.5),
a-CD11b (M1/70), a-CD11c (N418), a-CD103 (2E7), a-F4/80 (BMP),
a-CD90.2 (30H12), a-NKp46 (29A1.4), a-Gr-1 (RB6-8C5), a-RORgt (AFKJS-9),
a-CCR6 (140706, R&D systems), a-Sca-1 (D7, Invitrogen), a-T-bet (eBio4B10),
a-IFN-g (XMG1.2), a-IL-17A (eBio17B7), a-IL-22 (IH8PWSR), a-TNF-a (MP6-
XT22), a-IL-4 (11B11, BD PharMingen), and a-CD127 (A7R34).
RNA Extraction and Quantitative PCR
RNA was extracted from colon segments or purified cells with Trizol reagent
(Invitrogen) and complementary DNA (cDNA) generated with the cDNA
synthesis kit (Bioline). Quantitative PCRwas used to quantifymRNA transcripts
using TaqMan gene-expression assays (Applied Biosystems,Warrington, UK).
Gene expression was normalized to the expression of b-actin for generation
of DCt values, and relative abundance was quantified with the 2DCt method.
In Vivo Treatment of Mice
Antibody treatments comprised: 500 mg anti-TNF-a (clone XT3.11, days 0, 3, 6,
9, 12, 15, 18, and 21), 150 mg anti-IL23p19 (G23-8, eBioscience, days 0, 4, 8,
13, 16, and 20), 450 mg IL-17AmAb (17F3, days 0, 4, 8, 11, 15, 18, and 21), 1mg
CD90.2 mAb (30H12, days 0, 7, 14, 21, and 28), and 1 mg anti-IL-7R (A7R37,
days 0, 3, 6, 9, 12, 15, 18, and 21). Control-isotype clones usedwereMOPC-21
(mouse immunoglobulin G1 [IgG1]), HRPN (rat IgG1), 2A3 (rat IgG2a), and
LTF-2 (rat IgG2b). In the anti-CD40 model, 150 mg of mAb (clone FGK4.5) or
control isotype was administered to 6- to 8-week-old mice. Monoclonal anti-
bodieswere purchased fromBio XCell (West Lebanon, NH, USA) unless other-
wise stated and were administered intraperitoneally.
454 Pyrosequencing Analysis of Intestinal Microbiota 16S rRNA
Genes
DNA was extracted from frozen fecal pellets with the FastDNA SPIN Kit. 16S-
rRNA-gene PCR amplicons were generated for Lib-L 454 Titanium sequencing
with the use of barcoded primers targeting the V3–V5 regions of the 16S rRNA
gene. The primers and barcode sequences used are given in Table S2. PCR
products were generated with AccuPrime Taq DNA Polymerase High Fidelity
(Invitrogen). PCR cycling conditions were as follows: 94C for 2 min followed
by 20 cycles of 94C for 30 s, 53C for 30 s, and 68C for 2 min. PCR products
were then quantified with a Qubit 2.0 Fluorometer (Invitrogen), and equimolar
volumes of each were added to a master mix for sequencing.
Raw sequences were passed through the PyroTagger pipeline (Kunin et al.,
2010), which filters poor-quality reads, clusters sequences into OTUs at 97%
similarity, assigns taxonomic classifications to each OTU based on the Green-
genes (DeSantis et al., 2006) and SILVA (Pruesse et al., 2007) databases, and
trims them to a length of 400 bases. Further taxonomic classifications for
each OTU were obtained with the mothur software package (Schloss et al.,
2009) for classifying the sequences according to the Ribosomal Database
Immunity
T-bet Regulates Innate ImmunityProject (Cole et al., 2009) and SILVA (Pruesse et al., 2007) databases. After
processing and subsequent manual removal of suspect or chimeric OTUs,
33,528 sequences remained, which were split into 256 OTUs overall. The
median number of sequences per sample was 2,817 (range 1,781–3,884).
OTUs that were significantly differentially abundant between the TRUC and
two TRnUC mouse cohorts were identified with the Metastats program
(Schloss et al., 2009; White et al., 2009).
Helicobacter PCR
Bacterial DNA was extracted from feces with the QIAamp DNA stool minikit
(QIAGEN). H. typhlonius-specific PCR was performed with the use of primer
pairs that have been shown to amplify a 122 bp sequence of the 16S rRNA
gene in H. typhlonius, but not other Helicobacter species (Feng et al., 2005)
(50-AGGGACTCTTAAATATGCTCCTAGAGT-30 and 50-ATTCATCGTGTTTGAA
TGCGTCAA-30). The PCR conditions used were as follows: 95C for 30 s, 55C
for 30 s, and 72C for 30 s for 35 cycles.Helicobacter-genus-generic PCRwas
performed with the primer pair (50-TATGACGGGTATCCGGC-3 and 50-ATTC
CACCTACCTCTCCCA-30) (Beckwith et al., 1997). The 374 bp PCR product
generated by genus-generic primers was recovered from acrylamide gel for
subsequent DNA sequencing performed by an outside vendor (Charles River
Laboratories, Wilmington, MA, USA).
Bacterial Growth Conditions
H. typhlonius CCUG 48335 T was obtained from the culture collection of the
University of Goteborg, Sweden (Franklin et al., 2001) and was grown and
maintained either on blood agar plates (Oxoid, Hampshire, UK) containing
5% defibrinated horse blood (TCS Biosciences, Buckingham, UK) or in
brain-heart infusion broth supplemented with 1% yeast extract and 5% horse
serum. Cultures were incubated in an anaerobic atmosphere consisting of
80%N2, 10%H2, and 10%CO2 (DonWhitley Scientific, Shipley, UK). A total of
1–53 107 organismswere gavaged into selectedmice as described in the text.
Cell Culture
Unfractionated splenocytes (23 106/ml), mLN (13 105/ml), and cLP cells (13
105/ml) were cultured in RPMI-1640 medium (PAA Laboratories), supple-
mented with 10% FCS (PAA Laboratories), 50 mM 2-mercaptoethanol (Invitro-
gen), 2mM L-glutamine (Sigma-Aldrich), 1 mM sodium pyruvate (Invitrogen),
10 mM HEPES (Fisher Scientific), nonessential amino acids (Sigma-Aldrich),
100 IU/ml penicillin, and 100 mg/ml streptomycin (Invitrogen). Cells were
cultured in medium alone or in the presence of 20ng/ml recombinant IL-23
and/or TNF-a (R&D Systems). Cytokine concentrations in culture supernatants
were measured via ELISA (R&D Systems).
Ex Vivo Organ Culture
Three-millimeter punch biopsies (Miltex) were used to acquire full thickness
colonic biopsies. Three biopsies were cultured in 300 ml of RPMI supple-
mented with complete medium (as above) for 24 hr. Cytokine concentrations
in culture supernatants were measured by ELISA (R&D Systems).
Retroviral Transduction
CD4+ T cells from Tbx21/Ifng/ mice were cultured in Th0 conditions with
IL-2 only (20 ng/ml, R&D Systems, Abingdon, UK) and transduced with either
retrovirus encoding T-bet and green fluorescent protein (GFP) (RV-GFP-T-bet)
or control retrovirus encoding GFP only (RV-GFP) as described previously
(Szabo et al., 2000). Cells were sorted for GFP expression on day 5. Cells
were stimulated for 4 hr with PMA and ionomycin, and RNA was extracted
with Trizol reagent (Invitrogen).
Statistical Analysis
Nonparametric data were analyzed with the Mann-Whitney U test using
GraphPad Prism. Elsewhere, mean data are expressed with error bars denot-
ing SEM.
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